Table V.

Percent change in tumor size in patients with prolonged stable disease

	Histology	Tumor Location	Stable Disease Duration (months)	Timing of the Scan (Months from Treatment)	Optimal sequences measured	Tumor size	Change from baseline (%)
Pt 1	Glioblastoma Multiforme	Spinal Cord	5.3	Baseline	Enhancement	4.4a
				1.4		4.4	0
				2.6		4.6	↑ 5
				5.3		4.6	↑ 5
Pt 3	Choroid Plexus Carcinoma	Cerebrum	14.3	Baseline	Enhancement	1.21a
				1.3		1.30	↑ 7
				3.1		1.46	↑ 21
				5.9		1.48	↑ 22
				7.0		1.31	↑ 8
				11.4		1.22	↑ 1
				14.3		1.33	↑ 10
Pt 8	Glioblastoma Multiforme	Parietal lobe	15.9	Baseline	FLAIR	32.7b
				2.7		35.5	↑ 9
				8.1		29.1	↓ 11
				9.7		23.9	↓ 27
				11.1		30.5	↓ 7
				15.9		28.9	↓ 12
Pt 19	Astrocytoma, Anaplastic	Frontal lobe	10.6	Baseline	Enhancement	104.2b
				1.3		95.3	↓ 9
				2.7		75.1	↓ 28
				3.9		76.0	↓ 27
				5.4		75.9	↓ 27
				6.8		65.8	↓ 37
				9.5		80.0	↓ 23
Pt 26	Astrocytoma, NOS	Supratentorial, NOS	5.9	Baseline	Enhancement	28.1a
				2.6		31.9	↑ 14
				4.4		34.7	↑ 23
				5.9		34.7	↑ 23

^aTwo-dimensional measurement (cm²);

^bThree-dimensional measurement (cm³)